ArticleNature2024
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 107 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis.Frontiers in immunology · 2026Pooled it
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer.Annals of medicine · 2026Article
- Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study.Journal of personalized medicine · 2026Article
- Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.Journal of gastroenterology · 2026Article
- Immunometabolic Dysregulation in Obesity: Integrating Macrophage Polarization, Metabolic Reprogramming, and Gut Microbiota Crosstalk.Immunity, inflammation and disease · 2026Review
- The interplay between lipid metabolism, cancer progression and anti-cancer immunity.Experimental & molecular medicine · 2026Review
- Leptin Signaling at the Crossroads of Obesity, Immunity, and Cancer: Mechanistic Insights and Therapeutic Implications.Biomolecules & therapeutics · 2026Review
- Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.EMBO molecular medicine · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- An herbal formula, SH003 alleviates colorectal cancer through dual targeting of adaptive and innate checkpoints PD-L1/CD47.Cancer cell international · 2026Article
- M.globosa promotes lung cancer progression and M2 macrophage polarization through oxidative phosphorylation.NPJ precision oncology · 2026Article
- T cell dysregulation and remodeling in pediatric obesity and weight loss.bioRxiv : the preprint server for biology · 2026Article
- Inflammatory Memory of Adipose Tissue Macrophages: From CD68 Footprint to Cardiometabolic and Cancer Risk During Weight Cycling.International journal of molecular sciences · 2026Review
- Obesity-derived metabolites modulate anti-tumor immunity in the tumor microenvironment: from mechanisms to clinical applications.BMC medicine · 2026Review
- Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine-ZBTB5-mTORC1 axis.Nature cell biology · 2026Article
- Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer.Cancer biology & medicine · 2026Review
- Immune checkpoint blockade targets macrophage PD-1 to exacerbate metabolic dysfunction.Immunometabolism (Cobham, Surrey) · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
34 authors.
Jackie E BaderDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Melissa M WolfDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Gian Luca Lupica-TondoDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-4237-0750
Matthew Z MaddenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-4062-4427
Bradley I ReinfeldDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-4161-8301
Emily N ArnerDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3589-8829
Emma S HathawayDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
KayLee K SteinerDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-2188-6376
Gabriel A NeedleVanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8092-1074
Zaid HatemDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Madelyn D LandisDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Eden E FaneuffDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Amondrea BlackmanDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Elysa M WolfDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
Matthew A CottamDepartment of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Xiang YeDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8694-8710
Madison E BatesDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Kyra SmartDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Wenjun WangDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-0907-6282
Laura V PinheiroDepartment of Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Anthos ChristofidesDepartment of Medicine, Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.
DuPreez SmithDepartment of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.
Vassiliki A BoussiotisDepartment of Medicine, Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0002-3963-1518
Scott M HaakeDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3455-0791
Kathryn E BeckermannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-4616-6140
Kathryn E WellenDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-2281-0042
Cynthia A Reinhart-KingDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-6959-3914
C Henrique SerezaniDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Cheng-Han LeeDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Christa AubreyDepartment of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.
Heidi ChenDepartment of Biostatistics, Vanderbilt University, Nashville, TN, USA.
W Kimryn RathmellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Alyssa H HastyVanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-7302-8045
Jeffrey C RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. jeff.rathmell@vumc.org.ORCID 0000-0002-4106-3396
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MDiabetes, Endocrine, and MetabolismT32DK007314 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DORIS A STOFFERS, Patrick Seale · 1986 to 2026
$9.0MVANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7MAutoimmune Drivers and Protectors Team Science (ADAPTS)U01AI176244 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES, Jeffrey C Rathmell · 2023 to 2026
$5.1MDetermining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.U01CA272541 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Liza Makowski-Hayes, Joseph F PIERRE · 2022 to 2026
$5.1MExploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2015 to 2026
$4.7MNCI NIH HHS F30 CA239367NCI NIH HHS F30 CA247202NCI NIH HHS F31 CA261049NCI NIH HHS F99 CA274695NCI NIH HHS K00 CA234920NCI NIH HHS K00 CA253718NCI NIH HHS K08 CA241351NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA217987NCI NIH HHS R01 CA238263NCI NIH HHS R01 CA253329NCI NIH HHS U01 CA272541NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK105550NIDDK NIH HHS T32 DK007314NIDDK NIH HHS T32 DK101003NIDDK NIH HHS U24 DK059637NIGMS NIH HHS T32 GM007347
Abstract
Obesity is a leading risk factor for progression and metastasis of many cancers
Indexed as
NeoplasmsObesityProgrammed Cell Death 1 ReceptorTumor-Associated MacrophagesAnimalsAntigen PresentationB7-2 AntigenCD8-Positive T-LymphocytesCell Line, TumorFemaleGlycolysisHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsInflammation MediatorsB7-2 AntigenHistocompatibility Antigens Class IHistocompatibility Antigens Class IIImmune Checkpoint InhibitorsInflammation MediatorsMechanistic Target of Rapamycin Complex 1PDCD1 protein, humanPdcd1 protein, mouseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.